Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Original Investigation titled “Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial,”1 published online August 29, 2019, and in the November 2019 print issue, a minor coding error affected some of the secondary efficacy analysis data for the fulvestrant plus daily vistusertib and fulvestrant alone groups in the Table and in the Results section. The objective response rate should be 31.6% (95% CI, 21.4%-43.3%) for the fulvestrant plus daily vistusertib group and 26.0% (95% CI, 14.6%-40.3%) for the fulvestrant alone group, the clinical benefit rate should be 44.7% (95% CI, 33.3%-56.6%) for the fulvestrant plus daily vistusertib group and 38.0% (95% CI, 24.7%-52.8%) for the fulvestrant alone group, and the median duration of clinical benefit should be 11.9 months (95% CI, 10.9-13.7 months) for the fulvestrant plus daily vistusertib group. This article has been corrected online.
Data Errors in the Table and Results. JAMA Oncol. 2021;7(2):312. doi:10.1001/jamaoncol.2020.7104
Artificial Intelligence Resource Center